Last edition
News about "Biocon"
Biocon Join Hands with Tabuk Pharma to Commercialize its GLP -1 Products in Middle East
The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.
Biocon | 27/09/2024 | By Aishwarya | 151
Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok
Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.
Biocon | 28/05/2024 | By Aishwarya | 262
Biocon Signs Semi-Exclusive Distribution and Supply Deal for with Medix
Biocon Ltd. has signed a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda).
Biocon | 13/05/2024 | By Aishwarya | 109
Biocon Signs Exclusive Licensing and Supply Deal with Biomm for Drug Commercialization
Biocon Limited has signed an exclusive licensing and supply agreement with Biomm to commercialize its vertically integrated drug product, Semaglutide (gOzempic).
Biocon | 19/04/2024 | By Aishwarya | 102
EDQM conducts GMP inspection at Biocon's API site in Bengaluru
As per the filing, the inspection was held between September 12-14, 2022 and issued a list of deficiencies on October 5, 2022
Biocon | 10/10/2022 | By Sudeep Soparkar | 263
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy